Document is current
Any future updates will be listed below
-
Authors
Berton, Franziska
Rinnerthaler, Gabriel https://orcid.org/0000-0001-7438-1465
-
Funding
Funding for this research was provided by:
Medical University of Graz
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 17 December 2025
First Online: 14 January 2026
Conflict of interest
: G. Rinnerthaler: employment: none; leadership: none; stock and other ownership interests: none; honoraria: AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Seagen, Stemline; consulting or advisory role: AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, Stemline; speakers bureau: none; research funding (institution): AstraZeneca, Daiichi Sankyo, Stemline; patents, royalties, other intellectual property: none; expert testimony: none; travel, accommodations, expenses: Daiichi Sankyo, Gilead, Roche, Servier; other relationship: none. F. Berton declares that she has no competing interests.
